Research Use Only · Not for Human Consumption 25% off all peptides · applied automatically · Free Shipping on $250+ · View Lab Reports
Editorial still-life of a podcast microphone beside a white ceramic soup bowl and two clear vials on pale marble, hero for a recap of Huberman's GLP-1 episode with Scott Kanoski.

Huberman’s GLP-1 Episode With Scott Kanoski: Food Noise, Memory and What Nobody Knows

Scott Kanoski has spent most of his career studying GLP-1, the gut hormone that Ozempic and Wegovy are built to mimic. So the most surprising moment in his new Huberman Lab episode came early. Asked what “food noise” actually is,…

Scott Kanoski has spent most of his career studying GLP-1, the gut hormone that Ozempic and Wegovy are built to mimic. So the most surprising moment in his new Huberman Lab episode came early. Asked what “food noise” actually is, he said he’s never experienced it, finds the idea a bit strange, and can’t tell you whether the drugs quiet it by acting on the brain or simply by making you feel full. Huberman hasn’t experienced it either. Two neuroscientists, two hours on appetite, and the most-asked question about GLP-1 drugs stays open.

That honesty runs through the whole conversation, and it’s why the episode is worth your time if you research these compounds. Kanoski is a professor of human and evolutionary biology and neurobiology at the University of Southern California. His lab studies how hunger and memory interact, and his early GLP-1 work came out of the University of Pennsylvania alongside Harvey Grill and Matthew Hayes, one of the groups that worked out how these drugs suppress appetite. The episode, “How Food Choices Shape Memory, Cognition & Cravings,” was released on October 12, 2026 and runs about two hours.

A note on how we wrote this. Huberman’s official transcript sits behind his paywall and is still marked as under review, so we worked from the episode’s captions. We report what was said in our own words and give a timestamp for each point so you can hear it yourself. Where a claim deserved checking, we checked it against the published papers, and those checks are labeled.

The short version

  • Your body makes GLP-1 in two places, the gut and the brainstem, and Kanoski says the two systems seem to run independently (3:32).
  • The drugs put far more GLP-1 activity in your blood than you ever make yourself. Huberman’s “thousandfold” figure holds up for total drug levels (5:01).
  • There is no data on GLP-1 microdosing, in animals or in people (5:57).
  • Nobody knows what food noise is or where the drugs act to quiet it (16:46).
  • Kanoski isn’t worried about muscle and micronutrient loss, mainly because most people quit within two years. Real-world data say most quit over cost, not side effects (1:07:36).
  • Fullness is partly a memory. Patients with severe amnesia will eat three lunches in a row and still say they’re hungry (1:22:35).
  • Kanoski’s rat studies tie sweeteners, sugar and heat-processed food to memory problems. All of it is animal work, and one study is still unpublished.

Two GLP-1 systems that barely talk to each other

Kanoski starts with the basics (3:32). Natural GLP-1 is an incretin, a hormone released from the lower part of your intestine as you eat. A little comes out before the meal starts and more arrives during it. Besides blunting hunger, it helps regulate blood sugar by boosting insulin release when glucose is high.

There’s a second, separate source. A cluster of neurons in the brainstem, in a region called the nucleus tractus solitarius, makes its own GLP-1 and sends it throughout the brain. Gut GLP-1 and brain GLP-1 have very similar effects on hunger, but Kanoski says they appear to operate independently, with no strong connection between the two systems.

He also reminds listeners that the first GLP-1 drugs were built for blood-sugar control in diabetic patients, and weight was an afterthought (4:35). The weight effect came later, once it was clear the drugs also suppressed appetite.

Fact check: true, and understated. Kanoski says people have taken GLP-1 drugs for over a decade. It’s closer to two. Exenatide (Byetta) was approved for blood-sugar control in type 2 diabetic patients in 2005, liraglutide for weight management (Saxenda) in 2014, and semaglutide for weight (Wegovy) in 2021.

The “thousandfold” question

Huberman puts a number on how far the drugs go beyond nature (5:01). Ozempic and Wegovy, he says, raise GLP-1 levels about a thousand times higher than anything we experience naturally. Kanoski agrees and calls it supraphysiological.

Fact check: right order of magnitude. The FDA label for Wegovy gives an average steady-state semaglutide concentration of about 75 nanomoles per litre at the 2.4 mg weekly dose. A 2019 review of GLP-1 physiology (Müller et al., Molecular Metabolism) puts natural total GLP-1 at 5 to 10 picomoles per litre while fasting, rising to around 40 after a meal, with the active, intact form lower still. That puts the drug somewhere between roughly 1,900 and 7,500 times the natural level, depending on which natural number you compare against. Two caveats keep it honest. More than 99% of semaglutide in the blood is bound to albumin, and a 2023 estimate (Smits et al.) puts the free drug at roughly 180 to 350 picomoles per litre, which shrinks the gap to tens-fold. Potency per molecule also differs between the drug and the hormone. The same review gives native GLP-1 a half-life of one to two minutes, which explains why the body’s own hormone acts locally and briefly while the drugs linger for days.

In our June recap of Huberman’s peptides episode with Dr. Abud Bakri, we called this same thousandfold line a likely rhetorical exaggeration. For total drug in the blood, it isn’t. We were too quick to wave it off.

Kanoski’s summary of the downsides is short (5:18). The most common side effects are nausea and vomiting, and plenty of people tolerate them for a while and then stop. If the drugs have one main limitation, he says, it’s getting those side effects under control and keeping the effect going beyond the initial weight loss.

Microdosing: there’s no data, in anyone

This is the two minutes every GLP-1 researcher should hear (5:57). Huberman describes people taking far less than the prescribed amount, borrowing the word “microdosing” from psychedelics, either to avoid side effects or to save money. He adds that some of these drugs are expensive, though several are moving toward generics.

Kanoski says he isn’t aware of any animal or human data on microdosing at all. He calls himself old-fashioned: he wants large randomized controlled trials before he believes something works, and he points out that placebo effects are powerful. Huberman notes that drug companies have no reason to fund a trial designed to sell less drug. Kanoski adds that trials are expensive enough that nobody is likely to run one soon. Huberman’s conclusion is that the area runs on anecdotes.

He shares two of his own (7:10). He knows people at a healthy body weight taking small doses, or even full doses, for what they say are benefits to cognition and energy. And he has a friend with chronic fatigue syndrome who microdoses under a physician’s supervision, likes the effect, and dislikes the appetite suppression.

My take: the microdosing question hasn’t been answered in either direction because nobody has asked it in a controlled study. Any “microdose protocol” you see online rests on the same evidence as a number someone picked. The anecdotes are interesting. They’re also exactly the kind of evidence Kanoski says he doesn’t trust, and the placebo point cuts hardest here, since most of the claimed benefits (energy, focus, mood) are subjective.

Food noise: two neuroscientists who have never had it

Huberman has never taken a GLP-1 and wants to know what users mean when they say the drugs quieted their food noise (14:07). Is it simply feeling full?

Kanoski doesn’t experience food noise either (16:46). He has heard the same reports Huberman has, people saying the drug finally shut off the constant mental pull toward food. But he doesn’t know whether that relief comes from the drug binding receptors in higher brain regions involved in memory and decision-making, like the hippocampus and prefrontal cortex, or whether it’s simply the gut-to-vagus-nerve fullness signal doing its normal job. He calls not knowing where these drugs act one of the big gaps in his field (17:16).

My take: this is probably the most searched phrase in the whole GLP-1 conversation, and a researcher who has worked on these drugs since the mid-2000s says there’s no mechanism for it yet. That doesn’t make it imaginary. Huge numbers of users describe it. It does mean that anyone explaining exactly how food noise works, or which compound silences it best, is ahead of the published science.

How natural GLP-1 actually ends a meal

Kanoski explains that the body’s own GLP-1 probably works locally (14:29). It’s released by L cells in the intestine and acts right there on GLP-1 receptors sitting on the endings of the vagus nerve, the nerve that carries running updates from the gut to the brainstem during a meal: how stretched the stomach is, what nutrients are arriving.

His picture of fullness is an orchestra (15:48). Many signals combine to end a meal, some carried by the vagus and some not, and GLP-1 is one instrument. A big one, he says, working largely but not entirely through the vagus.

The evidence comes from Wolfgang Langhans’s group in Zurich (17:46). When they cut the sensory branch of the vagus coming up from the gut, injected GLP-1 no longer reduced food intake. When they knocked down GLP-1 receptors on the vagus, the animals ate bigger meals.

Then comes the caveat that matters for anyone researching the drugs (18:00). All of that applies to native GLP-1, which lasts minutes. A long-acting GLP-1 drug is a different story, Kanoski says: it stays in circulation far longer and can reach the brain.

Fact check: accurate. Rüttimann and colleagues (Endocrinology, 2009) found that GLP-1 injected into the abdominal cavity cut meal size in normal rats but not in rats whose vagal sensory fibres had been cut. Krieger and colleagues (2016) found that knocking down vagal GLP-1 receptors increased meal size and duration, sped up stomach emptying and raised blood sugar after meals. Kanoski’s own 2011 paper (Endocrinology) showed that rats without vagal sensory fibres still responded to liraglutide and exendin-4, but needed higher doses, which fits his point that the long-acting drugs only partly depend on the vagus.

Do the drugs even get into the brain?

Kanoski calls this one controversial in his field (8:34). In rodent work his group did between about 2005 and 2012, much of the appetite effect of the first-generation drugs came from action in the brain, meaning the drugs got in and activated receptors there. For newer drugs like Wegovy, he says, it’s less clear.

Some animal studies tag the drugs with fluorescent markers and find them piling up in the circumventricular organs, small brain areas that sit outside the blood-brain barrier. That supports the idea that the drugs mostly act there. Kanoski’s problem with those studies is technical: fluorescent signals fade, and brain tissue glows a little on its own, so the method can miss things. The better approach is radioactive labeling, which costs more. He credits Elizabeth Rhea, Bill Banks and colleagues at the University of Washington. Their work suggests the early drugs enter the brain readily and the newer ones less clearly, perhaps more slowly. The jury is still out, he says (10:19).

Fact check: accurate, and the newer data fit his description closely. Salameh, Rhea, Talbot and Banks (Biochemical Pharmacology, 2020) tracked radiolabeled GLP-1 drugs in mice for 60 minutes. The non-acylated drugs, such as exendin-4 and lixisenatide, crossed the blood-brain barrier. The acylated ones, liraglutide and semaglutide, did not measurably cross in that window. A 2024 follow-up from Rhea’s group (Tissue Barriers) found that tirzepatide didn’t appear to cross within an hour of intravenous injection but did enter slowly over six hours. Tirzepatide never comes up on air, so that last finding is ours to add, not Kanoski’s.

My take: for research purposes, this is the most useful section of the episode. If semaglutide barely enters brain tissue, then whatever it does to appetite and craving likely runs through the barrier-free areas, the vagus, or both. That’s an open question in the literature, and it means “this drug acts on your brain’s reward system” is an inference, not a measurement, for the newer compounds.

GLP-1 receptors in the memory and reward system

The receptors aren’t limited to appetite and blood-sugar regions, Kanoski explains (7:47). They’re dense throughout the brain, including the reward circuit (the ventral tegmental area, the striatum, the nucleus accumbens) and the hippocampus, which he calls one of his favorite brain regions. That’s why he sees possible future uses for GLP-1 drugs in substance use disorders, memory disorders and dementia. There’s a lot of preclinical support, he says, and clinical data are only starting to come out.

The hippocampus also carries receptors for insulin, ghrelin and leptin (55:24), so it gets both the fast nerve signal that you’re eating and the slower hormonal signal about your overall energy state. Kanoski argues that’s no accident: deciding what to eat and where to find it is a complex decision, and that’s the hippocampus’s territory.

Fact check: the biggest human test so far came up empty. EVOKE and EVOKE+, two Phase 3 trials of oral semaglutide in people with early Alzheimer’s disease, reported in late 2025 that the drug did not slow disease progression. Bakri brought up the disappointing Alzheimer’s result in June, which we covered in our Huberman peptides episode recap. The receptor anatomy is real. Whether the drugs do anything useful through it in humans is still unproven.

The real argument: muscle, micronutrients and quitting

The best exchange of the episode starts at 1:06:27, and it’s an actual disagreement.

Huberman says he’s read that GLP-1 drugs could bring back thiamine deficiency, plus other micronutrient gaps, in a modern population for the first time in decades, because people on the drugs eat less and often eat poorly. He worries about a population that ends up skinny fat, having lost muscle by not exercising while also running low on micronutrients, and suggests that could be as bad for the hippocampus as carrying the extra weight in the first place. He doesn’t name a study. It’s his concern, stated as one.

Kanoski says it isn’t a concern he shares (1:07:36), mostly because people don’t stay on these drugs long. A majority stop within two years, and to his knowledge no clinical trial has found micronutrient deficiency problems. On muscle, he’s careful. Lean-mass loss is one reason older people stop taking the drugs, but he’s explicit that the drugs don’t preferentially strip muscle (1:08:00). Lose weight by any method and you lose both fat and lean mass.

Huberman points out the trials only ran a year or two. Kanoski agrees and adds the bigger caveat (1:08:26): those trials were done in controlled settings, in diabetic patients, people with a clinically high BMI, or both. Now, he says, it’s a whole new world in which people who don’t need these drugs can get them. In lean users there could be plenty of problems that nobody has a handle on, because those trials haven’t been done and probably won’t be.

He closes the segment on a point the trials themselves make (1:10:21). Any weight-loss program should include nutrition and physical activity, and taking a pill alone isn’t the best way to lose weight. Most of the big trials built diet and exercise guidance into the protocol. Huberman predicts GLP-1 questions (whether to take them, what to eat on them, whether you can microdose, whether you can stop, what happens to muscle) will be a major theme for the next five to ten years. Kanoski adds that he believes semaglutide is approved for some teenagers (1:11:24).

Fact check: the quitting number is right, the reason is incomplete. A July 2024 real-world analysis from Prime Therapeutics found that only 15% of commercially insured adults who weren’t diabetic and started a GLP-1 for weight were still taking it two years later. So his claim that a majority stop within two years is, if anything, conservative. But Kanoski says people stop because of side effects, and the data point elsewhere. Gasoyan and colleagues (2025) reviewed 288 people who stopped semaglutide or tirzepatide within a year: 47.6% stopped over cost or insurance, 14.6% over side effects, 11.8% over shortages and 1.7% because the weight loss disappointed them.

Fact check: the teen approval is real. Wegovy’s US label was extended on December 23, 2022 to adolescents 12 and older with a BMI at or above the 95th percentile, based on the STEP TEENS trial (NEJM, 2022), where BMI fell 16.1% on the drug versus a 0.6% rise on placebo.

My take: both men are right, about different people. Kanoski’s comfort rests on short-term use in the population the trials studied. Huberman’s worry is about everyone outside it: lean users, long-term users, and people eating badly on a suppressed appetite. There’s no data on that group, and Kanoski himself says there probably never will be. For anyone researching these compounds, that’s the biggest open question the episode put on the table.

Fullness is partly a memory

This is Kanoski’s home turf, and it’s the most fascinating stretch of the conversation.

He describes a study from Suzanne Higgs and colleagues (27:06). People ate lunch, came back hours later, and some were asked to recall that lunch before a snack taste test. The ones who remembered their lunch ate fewer biscuits. The general rule: remembering a recent meal makes you eat less at the next one.

Then there’s the soup study from Jeff Brunstrom’s group (28:26). A hidden pump secretly refilled or drained each person’s soup bowl, so someone might see 300 millilitres and actually eat 500, or the reverse. Right after the meal, their hunger matched what they had really eaten, which Kanoski calls the wisdom of the body. A couple of hours later, it flipped: their hunger matched what they thought they had eaten.

And then the strongest story in the episode (1:22:35). Patients with dense amnesia, from damage to both sides of the medial temporal lobe, will eat a lunch, then a second, and sometimes start a third without remembering the first two. Asked how hungry they are, they still rate themselves around seven out of ten. Kanoski credits psychologist Paul Rozin with the study. His reading: the fullness signal from the gut arrives, but without the hippocampus the brain can’t work out what it means. Rats with hippocampal damage show a version of this too. Normal rats can learn to use their own hunger state as a cue, and rats with hippocampal lesions can’t, which Kanoski calls interoceptive agnosia. He adds that a high-fat, high-sugar diet impairs this kind of internal awareness as well.

Fact check: right in substance, two details off. The study is Rozin, Dow, Moscovitch and Rajaram (Psychological Science, 1998). Two densely amnesic patients readily ate a second lunch 10 to 30 minutes after the first and usually began a third. Their ratings were on a 1-to-9 scale where 7 meant moderately hungry, not a 0-to-10 scale. And the paper itself notes an earlier observation of the famous amnesic patient H.M. eating a second dinner, so Rozin’s was the first systematic study rather than the first report. The Brunstrom soup study checks out too (PLoS One, 2012: 300 versus 500 millilitres, with the reversal at two and three hours). One small flag on Higgs: the 2008 paper cited in the show notes used popcorn and cookie snacks, and we couldn’t confirm the pizza lunch Kanoski describes from the abstract.

Kanoski’s bigger idea ties these together (30:16). Mammals evolved competing for scarce food in complicated environments, so finding nutrients was a major event worth remembering: what you ate, what happened afterward, where to find it again. He thinks the hormones and nerves we usually study for metabolism and fullness are also wired to promote memory. You can find a cafe now, but the wiring is still there.

The acetylcholine staircase from Kanoski’s lab

The newest science in the episode is from his own lab (1:12:54). First, he points out that the vagus nerve isn’t sending one simple message that a meal has happened. Stretch sensors in the stomach and chemical sensors in the intestine send different signals through different kinds of neurons.

His group traced one route from the gut to memory: the vagus feeds the brainstem, the brainstem signals a region called the medial septum, and acetylcholine neurons there project into the hippocampus. Using fibre photometry to measure acetylcholine in eating rats, they found it rises as the animal holds, chews and swallows food, drops during pauses, and ends the meal higher than where it started, like a staircase (1:19:13). Kanoski’s interpretation is that the post-meal rise helps the animal remember the meal and where it happened, so it can come back.

Two details stand out. Junk food produced the same acetylcholine profile as healthy food. And stevia on its own, sweetness with no calories, didn’t trigger the release at all (1:20:36). They haven’t yet tested nutrients without taste, and his guess is that both are needed.

His lab has also built a vagus nerve stimulation device sutured to the stomach that fires only when the stomach stretches and contracts, meaning only while the animal eats (53:12). It rescued memory problems caused by an unhealthy diet in rats, and they’re now testing it in a rat model of Alzheimer’s disease. He calls the work early.

Our read, not said on air: the vagus is the same nerve natural GLP-1 uses to end a meal. Nobody on the episode asked whether the drugs, which shrink meals, change this meal-memory signal, and as far as we can tell it hasn’t been studied. That’s an open question, not a claim.

Fact check: one supporting claim didn’t hold up. Kanoski mentions a Taiwanese study linking vagus nerve surgery for ulcers to later dementia (52:38). The large Taiwanese cohort we found, Lin and colleagues (BMJ Open, 2018), followed about 156,000 vagotomy patients and concluded vagotomy was not associated with dementia risk. He may mean a different, smaller study, but we couldn’t verify the link, so count it as unconfirmed.

Sweeteners: the honest answer is that nobody knows

Huberman lays out three camps on artificial sweeteners (18:55). One says they’re harmful: they disturb blood sugar, damage the microbiome, and in the aspartame-scare version, do far worse. One says they’re inert in reasonable amounts. One is suspicious simply because they’re man-made. He says he’s not in the first camp, and that he’s drinking one as they talk.

Kanoski says it’s very controversial and no camp has definitive support. One proposed mechanism: sweet taste alone triggers a small, early insulin release before any nutrients arrive. In animal models, breaking the normal link between sweetness and calories can disturb appetite and blood-sugar control. In people, randomized trials haven’t settled whether sweeteners help or hurt weight loss, though swapping habitual sugary drinks for diet versions may help.

His own study gave adolescent rats stevia, acesulfame potassium or saccharin, which they drank voluntarily in amounts within FDA acceptable daily intake limits (22:08). As adults, eating a healthy diet with no sweeteners, the rats had memory impairments, which he calls unexpected and unexplained. They also had bigger insulin spikes when glucose was delivered past the mouth, and changes in the sweet-taste receptors on their tongues. He stresses the effects were modest, nothing dramatic.

Fact check: matches the paper, plus one detail he left out. Tsan and colleagues (JCI Insight, 2022) report what he describes, with comparable effects across all three sweeteners and no weight gain. The paper also found no robust changes to the gut microbiome, which counts against camp one’s microbiome argument, at least in rats.

His bottom line is that the evidence doesn’t support recommendations either way, and he doesn’t expect a trial to settle it soon. Then he added, “I consume Coke Zero regularly.” Huberman’s framing is that everyone gets to choose whether they’re in the experimental group or the control group.

Processed food, baked rat chow and one bacterium

Kanoski isn’t a fan of NOVA, the system human research uses to sort foods into four levels of processing (36:38). His complaint is that it isn’t mechanistic: it tells you a food is ultra-processed without telling you which processing step does the damage.

So his lab tested one step (37:19). They took an otherwise healthy rat diet and baked it for an hour at high heat, driving the Maillard reaction that browns food and creates compounds called advanced glycation end-products (AGEs). Rats fed this diet while young had memory impairments as adults. The heat had wiped out one population of gut bacteria, and putting that bacterium back reversed the memory problems. He repeatedly flags that this is a preprint, not yet peer reviewed.

Fact check: real, and unreviewed. The preprint was posted to bioRxiv in January 2026. Its abstract names the bacterium as Lactococcus lactis, reports that an AGE-blocking compound (alagebrium) also prevented the memory deficit, and says the effect happened without the rats becoming obese.

The rest of his microbiome work follows a similar logic (1:28:36). In rats raised on sugar, one genus, Parabacteroides, was roughly doubled and tracked with worse memory. When his group enriched it in rats that had never had sugar, those rats developed memory problems too (Noble et al., Translational Psychiatry, 2021). His junk-food model, which fed rats peanut butter cups and potato chips alongside high-fat, high-sugar chow, produced memory deficits that lingered even after the rats went back to a healthy diet (36:28). But he’s clear there’s no tidy list of good and bad bacteria yet, and the same species can look harmful in one study and helpful in another (1:33:54). The field is young: the Human Microbiome Project wrapped up around 2012, and microbiome papers on PubMed now number about 250,000.

Fact check: the ultra-processed figure is high for adults. Kanoski says over 60% of the calories many Americans eat come from ultra-processed foods (1:03:28). The CDC’s August 2025 data brief, using 2021 to 2023 national survey data, puts it at 55% overall: 53% for adults and 61.9% for children and teens. “More than half” is the accurate version for adults.

The Western-diet brain

In adult rats, a Western diet of about 35% of calories from fat and 15% from sugar can impair hippocampal memory within about a week (34:02). The hippocampus fails first, before other kinds of memory, which is why Kanoski calls it the canary in the coal mine. Give young rats a sugar solution making up about the same share of calories as a soft-drink habit, and the memory deficits persist into adulthood, even after the sugar stops (35:01).

In people, the evidence is correlational. Kanoski cites Richard Stevenson’s group, who found that healthy undergraduates with higher habitual sugar and saturated-fat intake had worse hippocampal memory (59:54). He’s quick to add that this doesn’t mean it can’t be reversed, and that people are bad at reporting what they actually eat. On dementia, long-term studies link midlife diet and metabolic health, including belly fat, to later risk, and a Western diet brings on symptoms earlier in Alzheimer’s-model rodents (45:34). He calls it a correlation, not a direct line, and his advice is to keep a healthy eating pattern across your life rather than switching once symptoms appear.

One hopeful note: in rats, exercise can reverse diet-induced memory deficits (48:25). Asked whether that’s metabolic or a direct brain effect, Kanoski says probably both.

Cravings can be retrained

The dopamine reward pathway responds to food based on your current state (1:43:39). Bland food triggers dopamine in a hungry animal, water in a thirsty one, salt in a salt-depleted one. Palatable foods simply hit harder. And preferences shift. Kanoski says people who cut way back on sugar often find their old favorites too sweet, and he argues that what we want to eat depends largely on what we choose to eat (1:46:31). The extreme version is conditioned taste aversion: pair sugar with nausea in a rat and its dopamine response to sugar disappears.

On food addiction, he stays neutral (1:49:50). The brain uses a common currency for drugs and palatable food, and by diagnostic criteria you could argue food addiction exists. But you have to eat every day, so it isn’t the same thing as drug addiction. He also mentions his own early brush with the sugar lobby: a press release about his unpublished early-life sugar study drew a public statement from the sugar industry, which he describes, with obvious sarcasm, as a pat on the back.

For GLP-1 research, this section connects back to the receptor map. The reward regions where dopamine does this work, the ventral tegmental area and nucleus accumbens, are the same regions dense with GLP-1 receptors, which is why addiction research is one of the areas being explored.

Quick hits

Oxytocin, another appetite peptide (1:56:43). Acting in the brainstem, oxytocin makes meals smaller, which Harvey Grill’s group and others established. Kanoski’s lab found a twist: people and rats eat more in company than alone, more with familiar company than strangers, and that social eating effect requires oxytocin signaling in the hippocampus. Turn it down and the effect disappears. Same peptide, opposite effect, depending on where it acts.

Fen-phen (1:40:21). Huberman describes the 1990s diet drugs as stimulants that gave people heart attacks. Kanoski gently corrects that to unwanted cardiovascular outcomes. Fact check: Kanoski is right. Connolly and colleagues (NEJM, 1997) described heart-valve disease in 24 women on fenfluramine-phentermine, eight of whom also had new pulmonary hypertension. The culprit was fenfluramine, a serotonin drug, and it was withdrawn in 1997. Phentermine is the stimulant. Kanoski thinks the episode made drug companies shy of weight drugs until around 2010, and says the alternatives since then have fallen out of favor because GLP-1 drugs work best.

How many adults are obese (1:41:24). Kanoski says over 40% of US adults are obese, maybe double the 1990s. Fact check: accurate. The CDC puts it at 40.3% for 2021 to 2023, against 22.9% in 1988 to 1994.

Meal timing (31:39). No single schedule works for everyone. Kanoski eats three meals a day, and his students range from grazers to one meal a day. He quotes weight researcher George Bray: the best diet is the one you can stick to.

Brain nutrients (1:27:21). Huberman lists omega-3s, polyphenols and enough protein. Kanoski agrees those are the established players, though his lab hasn’t tested omega-3s and mostly studies what goes wrong.

What the episode didn’t cover

If you came hoping for a GLP-1 drug comparison, this isn’t it. Tirzepatide, retatrutide and cagrilintide are never named, and neither are the GIP, glucagon or amylin pathways the newer compounds target. There’s no discussion of dosing, titration, oral versus injectable semaglutide, or what happens to weight after stopping. The only drugs mentioned by name are Ozempic, Wegovy and semaglutide.

For the next-generation picture, we compared the three main compounds in semaglutide vs tirzepatide vs retatrutide and covered the trial numbers in peptides for weight loss. If those are part of your research, Peptigo supplies Retatrutide, Semaglutide, Tirzepatide and Cagrilintide as research compounds, and every compound we carry is third-party tested by Janoshik, with the lab results posted.

My take: was it worth two hours?

For GLP-1 research, yes, and the reason is the same one that made the Bakri episode worthwhile. A scientist who has studied these drugs for most of two decades kept marking the edge of what’s known: where the drugs act in the brain, what food noise is, what microdosing does, what long-term use means for lean people. Most GLP-1 content online fills those gaps with confidence. Kanoski left them open, and that’s more useful.

If you’re short on time, listen to the first 20 minutes and then jump to 1:04:32 for the muscle and micronutrient debate. If you have more, the memory material from 1:12:54 to 1:26:21 is the part you’ll keep thinking about. The idea that fullness is partly something you remember changes how you think about appetite, and so, by extension, about drugs that change appetite.

In June, Bakri raised the question of what supercharged GLP-1 signaling might do to learning and memory over the long run. Four months later, Huberman sat down with a scientist who studies GLP-1 receptors in the memory system for a living. His honest answer was that nobody knows yet.

This article recaps a public Huberman Lab podcast episode for educational and informational purposes. Statements are attributed to the hosts or to the published research named, and many of the findings discussed come from animal studies. All Peptigo products are sold strictly for laboratory and research use only, not for human or veterinary use, and nothing here is medical advice. Peptigo does not make medical claims. Consult a qualified professional before any decision involving these compounds.

Episode: “How Food Choices Shape Memory, Cognition & Cravings” with Dr. Scott Kanoski, Huberman Lab, October 12, 2026. Timestamps refer to the YouTube version.

LT
Peptigo Lab Team

Written by our in-house lab team and cross-checked against the current literature. If you spot an error, email research@peptigopeptides.is.

Select size

Choose a vial size
Added to cart ✓ View cart